CAS 284461-73-0
:Sorafenib
Descrizione:
Sorafenib è un inibitore della tirosina chinasi a piccole molecole utilizzato principalmente nel trattamento di alcuni tipi di cancro, inclusi il carcinoma a cellule renali e il carcinoma epatocellulare. La sua formula chimica è C21H16ClF2N3O3 e presenta una struttura complessa che include un anello di piridina, un gruppo fenilico e una parte di urea. Sorafenib agisce inibendo più chinasi coinvolte nella proliferazione delle cellule tumorali e nell'angiogenesi, mirando specificamente alla chinasi RAF e a varie chinasi di tirosina recettoriali. Questo approccio multi-target aiuta a interrompere le vie di segnalazione che promuovono la crescita e la metastasi del cancro. Sorafenib è tipicamente somministrato per via orale e ha una biodisponibilità moderata, con la sua farmacocinetica influenzata da fattori come l'assunzione di cibo. Gli effetti collaterali comuni includono affaticamento, diarrea e reazioni cutanee. A causa del suo meccanismo d'azione e delle applicazioni terapeutiche, Sorafenib rappresenta un significativo progresso nelle terapie mirate contro il cancro, sebbene il suo uso possa essere limitato dallo sviluppo di resistenza e dalla necessità di un attento monitoraggio del paziente.
Formula:C28H24ClF3N4O6S
InChI:InChI=1/C21H16ClF3N4O3.C7H8O3S/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25;1-6-2-4-7(5-3-6)11(8,9)10/h2-11H,1H3,(H,26,30)(H2,28,29,31);2-5H,1H3,(H,8,9,10)
InChI key:InChIKey=MLDQJTXFUGDVEO-UHFFFAOYSA-N
SMILES:O(C=1C=C(C(NC)=O)N=CC1)C2=CC=C(NC(NC3=CC(C(F)(F)F)=C(Cl)C=C3)=O)C=C2
Sinonimi:- 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-
- 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
- 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide 4-methylbenzenesulfonate
- 4-[4-[[4-Chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
- 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-Pyridinecarboxamide
- Bay 43-9006
- N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea
- Nevaxar
- Sorafenib base
- Sorafenib
- SORAFENIB TOLSYLATE
- Sorafenib free base for research
- SORAFENIB-D3
- SORAFENIB MESYLATE
- BAY-43-900
- Sorafenib Tosylate(TINIBS)
- N-[4-Chloro-3-(trifluoromethyl)phenyl]-({4-[2-(N-methyl-carbamoyl)(4-pyridyloxy)]phenyl}amino)-carboxamide
- RAF1 KINASE INHIBITOR II
- SORAFENIB(FORR&DONLY)
- Sorafenib Tosylate for research
- Vedi altri sinonimi
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
14 prodotti.
Sorafenib
CAS:Formula:C21H16ClF3N4O3Purezza:>98.0%(T)(HPLC)Colore e forma:White to Light yellow powder to crystalPeso molecolare:464.834-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
CAS:Formula:C21H16ClF3N4O3Purezza:99%Colore e forma:SolidPeso molecolare:464.8249Sorafenib
CAS:Sorafenib (Bay 43-9006) is a multikinase inhibitor that inhibits Raf-1, B-Raf, VEGFR2, VEGFR3, VEGFR4, PDGFRβ, FLT3, c-Kit, and others (IC50=6/22/90/15/20/20/57Formula:C21H16ClF3N4O3Purezza:98% - 99.89%Colore e forma:SolidPeso molecolare:464.82Sorafenib
CAS:SorafenibFormula:C21H16ClF3N4O3Purezza:98%Colore e forma: white solidPeso molecolare:464.82g/molSorafenib
CAS:Formula:C21H16ClF3N4O3Purezza:≥ 95.0%Colore e forma:White, off-white or light-yellow solidPeso molecolare:464.83Sorafenib
CAS:Prodotto controllatoFormula:C21H16ClF3N4O3Colore e forma:White SolidPeso molecolare:464.82Ref: 4Z-S-272
5mgPrezzo su richiesta10mgPrezzo su richiesta25mgPrezzo su richiesta50mgPrezzo su richiesta100mgPrezzo su richiestaSorafenib-d4
CAS:Prodotto controllatoFormula:C21H12D4ClF3N4O3Colore e forma:NeatPeso molecolare:468.85Sorafenib - Bio-X ™
CAS:Sorafenib is a drug that belongs to the class of multikinase inhibitors. It inhibits a number of kinases, including the Mcl-1 protein, which is involved in apoptosis along with blocking picolinic acid (PA), an endogenous metabolite involved in apoptosis signal transduction. Sorafenib also binds to epidermal growth factor receptor (EGFR) on the surface of cancer cells, inhibiting the production of proteins that are required for angiogenesis, thus blocking the formation of new blood vessels. Sorafenib may also inhibit P-glycoprotein (Pgp) activity. Overall, these cytotoxic effects give Sorafenib anti-tumor properties, inhibiting angiogenesis and cellular transformation, which are the two main processes of tumor growth and metastasis. Sorafenib has been shown to be effective against a range of solid tumors such as breast, prostate and lung cancers and is also used for the treatment of metastatic colorectal cancer and renal cell carcinoma. A combination therapy group found that sorafenib was more effective when used with interferon alfa-2b for the treatment of advanced renal cell carcinoma. Sorafenib also has the potential for drug interactions with other drugs that are metabolized by cytochrome P450 enzymes. Sorafenib is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready to use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.Formula:C21H16ClF3N4O3Purezza:Min. 98%Colore e forma:PowderPeso molecolare:464.82 g/molSorafenib
CAS:Sorafenib is a drug that belongs to the class of multikinase inhibitors. It inhibits a number of kinases, including the Mcl-1 protein, which is involved in apoptosis along with blocking picolinic acid (PA), an endogenous metabolite involved in apoptosis signal transduction. Sorafenib also binds to epidermal growth factor receptor (EGFR) on the surface of cancer cells, inhibiting the production of proteins that are required for angiogenesis, thus blocking the formation of new blood vessels. Sorafenib may also inhibit P-glycoprotein (Pgp) activity. Overall, these cytotoxic effects give Sorafenib anti-tumor properties, inhibiting angiogenesis and cellular transformation, which are the two main processes of tumor growth and metastasis. Sorafenib has been shown to be effective against a range of solid tumors such as breast, prostate and lung cancers and is also used for the treatment of metastatic colorectal cancer and renal cell carcinoma. A combination therapy group found that sorafenib was more effective when used with interferon alfa-2b for the treatment of advanced renal cell carcinoma. Sorafenib also has the potential for drug interactions with other drugs that are metabolized by cytochrome P450 enzymes.
Formula:C21H16ClF3N4O3Purezza:Min. 98.0 Area-%Colore e forma:White PowderPeso molecolare:464.82 g/mol
![4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb%2FDA0039KS.jpg&w=3840&q=75)
